Breaking the synergism of iron overload and miR-122 to rescue lipid accumulation and peroxidation in MASLD
MASLD is a multifactorial disease with specific subtypes being featured by hepatic iron overload and loss of miR-122, a liver-specific microRNA regulating hepatic lipid homeostasis. Previously we reported the mechanism of iron overload decreasing miR-122. Interestingly, we found that mice lacking miR-122 were highly sensitive to iron overload-induced steatosis and fibrosis. The present study aimed to disclose the downstream mechanisms and the preventive measures targeting miR-122. We first validated the decreases in iron-related genes and miR-122 in MASLD. By using LC-MS/MS and gas-chromatography, we found that the combination of miR-122 knockout and iron overload significantly increased the production and peroxidation of polyunsaturated fatty acids (PUFAs). However, miR-122 knockout itself only incurred lipid accumulation, suggesting a synergistic effect of miR-122 knockout and iron overload in lipid peroxidation. We then located the key enzymes involved in PUFA production and peroxidation by the transcriptome and proteome analysis. Mechanistically, miR-122 and iron regulated fatty acid synthesis through Aacs, fatty acid desaturation through Fads2, and PUFAs oxidation through CYPs. Re-supplementation of miR-122 by recombinant adeno-associated virus or agomir effectively broke the synergism of miR-122 knockout and iron overload in vivo. We further designed a miR-122 expression reporter cell model for high-throughput screening on 2543 natural compounds, and eventually found and validated that the dihydroberberine could upregulate miR-122 expression and correct iron overload-induced lipid disorders. These results identified the synergistic role of miR-122 and iron in PUFAs production and peroxidation, and also proposed the potential application of dihydroberberine as a preventive and therapeutic candidate for MASLD.
Authors
- Yuxiao Tang (ORCID: https://orcid.org/0000-0001-7576-8928)
- Jianxin Yang
- Yan Sun (ORCID: https://orcid.org/0000-0001-7021-7799)
- Dongyao Wang (ORCID: https://orcid.org/0000-0002-5852-2640)
- Hui Shen (ORCID: https://orcid.org/0000-0002-6684-8595)
- Zelong Gao (ORCID: https://orcid.org/0000-0002-8724-8396)
- Yifeng Chai (ORCID: https://orcid.org/0000-0001-9032-3089)
- Hongwei Zhang (ORCID: https://orcid.org/0000-0001-6375-5003)
- Min Li (ORCID: https://orcid.org/0000-0003-1247-0475)
- Feng Xie (ORCID: https://orcid.org/0009-0006-4759-0097)
- Hui‐Wen Wu (ORCID: https://orcid.org/0000-0001-7226-2251)
- Jianxin Qian (ORCID: https://orcid.org/0000-0002-0157-1281)
- Minliang Wu (ORCID: https://orcid.org/0000-0002-7077-6686)
- Weili Wang
- Chenghua Wu
- Chenqi Li (ORCID: https://orcid.org/0000-0002-1289-8423)
Institutions
- Second Military Medical University (CN)
- Shanghai Chest Hospital (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Longhua Hospital Shanghai University of Traditional Chinese Medicine (CN)
- Eastern Hepatobiliary Surgery Hospital (CN)
- The Sixth People's Hospital of Zhengzhou (CN)
Publication Details
- Journal
- Pharmacological Research
- Published
- 2025-04-06
- DOI
- https://doi.org/10.1016/j.phrs.2025.107728
- Citations
- 4
- Primary Topic
- MicroRNA in disease regulation
- Type
- article
- Field-Weighted Citation Impact
- 3.75